Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > CR at 450

<< Previous

Bullboard Posts

Next >>

Comment by Rumpl3StiltSkinon Jul 23, 2022 9:10am

285 Views

Post# 34845254

RE:CR at 450

Hmm, 1433 isn't really a drug per se. Since it works at the cellular level it should work 100% It is a bit of a puzzle of why the %s are as low as they are currently. It has more to do with the patients and the Clinicians that 1433, IMO. To me it means keep trying, if 1433 didn't work the first time give it another go. I hope Docs will understand that.

For this Study 2? to be successful I think the minimum %s we'd need are in the 30s. With 2 tries per patient I think that should be doable. I think Dr. M said 30% would be 'great'?

<< Previous

Bullboard Posts

Next >>

Sony’s Alpha 1 II: A new professional photography standard?